Prepared by ILRI's Vaccine team, 1 July 2014

1. Current
and
future
animal
vaccine
research
ac2vi2es
at
ILRI
Vaccine
Biosciences
Interna.onal
Livestock
Research
Ins.tute
1st
July
2014
Contact:
ilri-­‐vaccines@cgiar.org

2. ILRI
Nairobi
campus
A lab in Africa at the foot of Kenya’s Ngong Hills
★

3. Google’s
view
of
the
ILRI
campus
-­‐
laboratory
and
farm
facili2es
BecA
-­‐
ILRI
Labs
Secure
Animal
Disease
Facility
Farm
and
paddocks

4. Importance
of
animal
health
research
in
the
developing
world
Ø Livestock
offer
a
powerful
pathway
out
of
poverty
for
~750
million
poor
farmers
in
South
Asia
and
Africa
by
providing
nutri2onal
and
economic
security.
Ø Infec2ous
livestock
diseases
feature
prominently
among
the
constraints
faced
by
livestock
agriculture.
u Endemic
diseases
u Epidemic/pandemic
diseases
u Trans-­‐boundary
diseases
u Emerging
and
re-­‐emerging
diseases
u Zoono2c
diseases
and
food
safety
Ø Vaccines
are
the
most
effec2ve
disease
interven2on
deployed
especially
in
developing
countries
but
most
vaccines
if
they
exist
are
sub-­‐op2mal.
Ø For
many
reasons
diseases
are
neglected
problems
in
affected
countries,
a
situa2on
exacerbated
by
a
general
lack
of
investment,
vaccine
R
&
D
and
manufacturing
capacity.

5. List
of
current
ILRI
high
priority
diseases
targeted
for
control
Ø African
swine
fever
(ASF)
–
swine
u African
disease
threatens
the
global
$150
billion/year
pig
industry
Ø Contagious
bovine
pleuropneumonia
(CBPP)
–
caZle
u Regional
losses
to
CBPP
amount
to
~
$60
million/year
Ø East
Coast
fever
(ECF)
–
caZle
u Regional
losses
exceed
$300
million/year;
kills
~
1million
caZle/year
Ø Peste
de
pe2ts
ruminants
(PPR)
–
small
ruminants
u Losses
in
Kenya
alone
amount
to
~
$13
million/year
Ø Ri_
Valley
Fever
(RVF)
–
small
ruminants,
caZle
and
human
u 2006/7
outbreak
in
Kenya
cost
~
$30
million
o
309
human
cases
in
Kenya,
Somalia
and
Tanzania;
140
deaths
Vaccines
save
lives
and
livestock
and
contribute
to
food
security
and
poverty
allevia5on

6. ILRI’s
vaccine
R
&
D
pathway
to
impact
Marke&ng)
Market)
assessment)
Proof0of0principle)
laboratory/field)
Clinical)
development)
Manufacturing)
Product)development)partnerships))Research)partnerships)
Disease)selec&on) Lead)vaccine)molecules) Vaccine)op&miza&on) Scaled0up)produc&on) Delivery)
NARS,&Universi.es,&ARIs,&Regional&and&
sub7regional&R&D&organiza.ons,&PPP&&
Target)product)profile) Phase)I,)II,)III)trials) Regulatory)processes) Con&nued)monitoring)
PPP,&Private&sector,&Regional&networks,&FAO,&OIE,&PANVAC,&
AU7IBAR,&NARs,&NGOs&
Ø ILRI’s
compara2ve
advantage
is
mainly
in
the
discovery
phase
to
proof-­‐of-­‐principle
under
laboratory
and
field
condi2ons.
Ø Different
entry
points
in
pathway
depending
on
disease
targeted
for
control.
u Improvement
of
exis2ng
vaccines
u Development
of
subunit
vaccines
u Laboratory
and
field
based
diagnos2cs

7. Vaccines
save
lives
and
livestock
and
contribute
to
food
security
and
poverty
allevia5on
ILVAC
–
plan2ng
the
orchard
BASIC&RESEARCH&
&
Increase&our&knowledge&base&
&
“Knowledge&lays&the&founda>on&
for&science&&&innova>on”&
APPLIED&RESEARCH&!
Develop&new&vaccines&&&diagnos>cs&
!
“Vaccines&are&highly&effec>ve&an>I
disease&interven>ons”&
! Study&hostIpathogen&interac>ons&
&
! Map&immune&responses&to&infec>on&
! Characterize&pathogen&virulence&
! Inves>gate&disease&epidemiology&
! Dissect&pathogen&biology&&&
diversity&
! Iden>fy&candidate&vaccine&and&
diagnos>c&molecules&
! Assess&candidate&vaccine&molecules&
! Assess&aMenuated&pathogens&
! ThermoIstabilize&vaccines&
! Develop&easy&to&use&diagnos>c&tools&
! Assess&different&vaccina>on&
systems&
! Facilitate&transla>on&of&research&
outputs&to&commercial&products&

8. Vaccines
save
lives
and
livestock
and
contribute
to
food
security
and
poverty
allevia5on
ILVAC
-­‐
a
vaccine
plaeorm
An#body(technologies(
Vaccine(technologies(
Cellular(technologies(
Diagnos#c(technologies(
Genomic(technologies(
Contagious(bovine(
pleuropneumonia((
East(Coast(fever(
African(swine(fever((
Consor#a(for(research(&(product(development(and(capacity(development(
Private(sector(
GALVmed(
CRPs(
NARS(
InterEgov(
agencies(
Improved(vaccines(and(
diagnos#c(tools(
Peste(des(pe##s(ruminants((
RiF(Valley(fever(
Infec#ous(disease(
research:(basic(&(applied(
ILVAC(–(a(vaccine(plaIorm(

9. A
poreolio
of
innova2on
and
vaccine
related
technology
plaeorms
Ø Op2mizing
exis2ng
vaccines
u Thermostabiliza2on
of
aZenuated
viral
vaccines
u Establishing
quality
control
and
process
improvement
Ø Reverse
vaccinology
and
immunology
u Iden2fica2on
of
candidate
vaccine
an2gens
u Assessing
protein
and
gene-­‐based
vaccine
formula2ons
Ø Pathogen
&
livestock
genomics
u Host
and
pathogen
gene
expression
profiles
u Pathogen
popula2on
structure
Ø Synthe2c
genomics
u Manipula2ng
bacterial
genomes
u AZenua2ng
viruses
by
genome
engineering
Yeast&with&M.#myc&LC&
genome&
(Delete&puta5ve&&
virulence&factors)&
Less&virulent&M.#myc&LC&
ACTGGTACGTAGGGCATCGA
TCGACATGATAGAGCATATA
GCATGACGATGCGATCGACA
GTCGACAGCTGACAGCTGAG
GGTGACACCAGCTGCCAGCT
GGACCACCATTAGGACAGAT
GACCACACACAAATAGACGA
TTAGGACCAGATGAGCCACA
TTTTAGGAGGACACACACCA
Bioinformatics
tools
Predict gene
sequences and
list candidate
vaccine antigens
Test experimental vaccine
Clone genes of
vaccine interest
(100’s of genes)
Filter genes via
immunological
assays
Pathogen genome mining
(1000’s of genes)
Molecular immunology
tools to assess immune
responses in cattle
(10’s genes)

10. A
research
center
of
excellence
-­‐
a
vaccine
ini2a2ve
at
ILRI
Ø Exploit
high-­‐end
science
and
technologies
to
accelerate
vaccine
development
Ø Support
each
disease
focus
with
program
level
funding
Ø Develop
global
research
and
product
development
partnerships
Ø Provide
fellowships
for
training
and
scien2fic
leadership
in
developing
countries
Ø Help
build
ins2tu2onal
capacity
for
vaccine
R
&
D
in
developing
countries
Ø S2mulate
learning
between
veterinary
and
human
vaccine
communi2es
Ø Provide
an
incubator
type
approach
to
leverage
ILRI
facili2es

11. Why
ILRI
for
a
vaccine
ini2a2ve?
Ø Modern
bio-­‐molecular
laboratory
facili2es
Ø
Secure
animal
disease
facili2es
for
large
and
small
animals
Ø
Loca2on
and
access
to
diverse
pathogens
indigenous
livestock
and
wildlife
Ø Track
record
in
teaching,
training
and
capacity
building
Ø Ongoing
projects
o Vaccine
development
against
neglected
livestock
diseases
o One
Health
and
agricultural
associated
human
diseases
o Highly
relevant
field
research
Ø Networks
with
academic,
na2onal,
regional
and
interna2onal
organiza2ons,
including
the
public,
private
and
development
sectors

12. The
ILRI
Vaccine
Biosciences
group

13. The
presenta.on
has
a
Crea.ve
Commons
licence.
You
are
free
to
re-­‐use
or
distribute
this
work,
provided
credit
is
given
to
ILRI.
ilri.org
Box 30709, Nairobi 00100, Kenya
Phone: + 254 20 422 3000
Fax: +254 20 422 3001
Email: ILRI-Kenya@cgiar.org
Box 5689,Addis Ababa, Ethiopia
Phone: +251 11 617 2000
Fax: +251 11 617 2001
Email: ILRI-Ethiopia@cgiar.org
other offices
China • India • Mali
Mozambique • Nigeria • Tanzania
Thailand • Uganda • Vietnam
Better lives through livestock
ILRI is a member of the CGIAR Consortium
BeKer
lives
through
livestock
ilri.org